U.S. markets closed

Mountain Crest Acquisition Corp. II (MCADR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9000+0.0100 (+1.12%)
At close: 1:20PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8900
Open0.7250
Bid0.6500 x 1200
Ask0.9000 x 1800
Day's Range0.8938 - 0.9000
52 Week Range0.8938 - 0.9000
Volume1,401
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Better Therapeutics To Go Public Via Mountain Crest SPAC Deal
      Benzinga

      Better Therapeutics To Go Public Via Mountain Crest SPAC Deal

      Better Therapeutics Inc, a company developing prescription-only smartphone-based treatments for Type 2 diabetes and high blood pressure, has agreed to go public through a merger with a blank-check company Mountain Crest Acquisition Corp II (NASDAQ: MCAD) The transaction is expected to close during this summer, and the combined entity will operate under the Better Therapeutics moniker and trade on the NASDAQ under the symbol 'BTTX.' The deal values Better Therapeutics at $187 million, including debt. The merger is expected to deliver up to $113 million in proceeds, including private investment rounds collecting $56 million from Farallon Capital, RS Investments, Sectoral Asset Management, Monashee Investment, and other undisclosed investors. Better Therapeutics, founded in 2015, develops software for apps that treat patients, calling it prescription digital therapeutics. Its apps can be prescribed to help treat diabetes, heart disease, and other conditions using cognitive behavioral therapy. The company's first prescription digital therapeutics (BT-001) is under evaluation in a pivotal trial to treat type 2 diabetes used under physician supervision. The SPAC has raised $57.5 million in its initial public offering in January. Price Action: MCAD shares are down 0.25% at $9.92 on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNIH Starts Study On Allergic Reactions Risk To Pfizer/BioNTech, Moderna COVID-19 VaccinesLumiraDx Withdraws 0M IPO In Favor Of B SPAC Merger: Bloomberg© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.